Compare Becton Dickinson and Co (BDX) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Becton Dickinson and Co trades at $155.79 (market cap $41.51B), while KraneShares Electric Vehicles and Future Mobility trades at $30.09. The key difference: Becton Dickinson and Co pays a 2.79% dividend while KraneShares Electric Vehicles and Future Mobility pays none. Which is the better fit depends on your goals.
| BDX | KARS | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.39 | $38.01 |
52-Week Low | $135.49 | $23.10 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
KARS trades at $29.72, down 2.8% in the last 24 hours, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The stock lacks key financial ratio data, but recent news highlights global EV sales growth, particularly in Europe and China, driven by high fuel prices and policy support. However, competition from Chinese automakers and potential US regulatory barriers present challenges.
The outlook for KARS is mixed, with positive industry tailwinds from rising EV adoption offset by technical weakness and competitive risks. Investment opportunities lie in exposure to the expanding EV market, but investors face volatility from geopolitical factors and shifting consumer demand. Caution is warranted given the bearish technical signals and lack of fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
